883107-68-4Relevant academic research and scientific papers
BIARYL KINASE INHIBITORS
-
Page/Page column 138; 139, (2017/05/07)
The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
BIARYL KINASE INHIBITORS
-
Page/Page column 139; 140, (2015/11/02)
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
An orally available BACE1 inhibitor that affords robust CNS Aβ reduction without cardiovascular liabilities
Cheng, Yuan,Brown, James,Judd, Ted C.,Lopez, Patricia,Qian, Wenyuan,Powers, Timothy S.,Chen, Jian Jeffrey,Bartberger, Michael D.,Chen, Kui,Dunn, Robert T.,Epstein, Oleg,Fremeau, Robert T.,Harried, Scott,Hickman, Dean,Hitchcock, Stephen A.,Luo, Yi,Minatti, Ana Elena,Patel, Vinod F.,Vargas, Hugo M.,Wahl, Robert C.,Weiss, Matthew M.,Wen, Paul H.,White, Ryan D.,Whittington, Douglas A.,Zheng, Xiao Mei,Wood, Stephen
supporting information, p. 210 - 215 (2015/03/04)
BACE1 inhibition to prevent Aβ peptide formation is considered to be a potential route to a disease-modifying treatment for Alzheimer's disease. Previous efforts in our laboratory using a combined structure- and property-based approach have resulted in th
AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
-
Page/Page column 82; 83, (2013/04/10)
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, L, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE
-
Page/Page column 59, (2011/10/10)
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I): wherein A1, A2, A3, A4, A5, A6, R2, R7, X, Y and Z of Formula (I) are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).
